NanoViricides, Inc (NNVC) Stock AnalysisNNVCStock AnalysisNanoViricides, Inc

NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, NanoViricides Inc is not a strong buy due to its low current price of $1.24 and a very low RSI of 20.684, indicating it is oversold. However, the potential upside is significant with an analyst price target of $6, suggesting a possible 384% increase. The main risk is its ongoing losses, with a net income of -2220719.00 USD in Q2 2026, which raises concerns about its financial health.